{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T02:02:42Z","timestamp":1777341762274,"version":"3.51.4"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T00:00:00Z","timestamp":1566604800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2019,12]]},"DOI":"10.1007\/s10147-019-01526-7","type":"journal-article","created":{"date-parts":[[2019,8,24]],"date-time":"2019-08-24T10:02:31Z","timestamp":1566640951000},"page":"1596-1604","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["An open-label, phase 1 study of androgen receptor antagonist, apalutamide in Japanese patients with metastatic castration-resistant prostate cancer"],"prefix":"10.1007","volume":"24","author":[{"given":"Tomohiro","family":"Tsuchiya","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Keiichiro","family":"Imanaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuki","family":"Iwaki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ryo","family":"Oyama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuyoshi","family":"Hashine","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akito","family":"Yamaguchi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7943-1564","authenticated-orcid":false,"given":"Hiroji","family":"Uemura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,8,24]]},"reference":[{"issue":"6","key":"1526_CR1","doi-asserted-by":"publisher","first-page":"394","DOI":"10.3322\/caac.21492","volume":"68","author":"F Bray","year":"2018","unstructured":"Bray F, Jerlay J, Soerjomataram I et al (2018) Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortaility worldwide for 36 caancers in 185 countries. CA Cancer J Clin 68(6):394\u2013424","journal-title":"CA Cancer J Clin"},{"key":"1526_CR2","unstructured":"Foundation for promotion of cancer research (2014) Cancer statistics in Japan\u20142014. Available via DIALOG. \nhttps:\/\/ganjoho.jp\/data\/reg_stat\/statistics\/brochure\/2014\/cancer_statistics_2014_fig_E.pdf\n\n. Accessed Nov 2018"},{"issue":"9","key":"1526_CR3","doi-asserted-by":"publisher","first-page":"884","DOI":"10.1093\/jjco\/hyv088","volume":"45","author":"M Hori","year":"2015","unstructured":"Hori M, Matsuda T, Shibata A et al (2015) Cancer incidence and incidence rates in Japan in 2009: a study of 32 population-based cancer registries for the Monitoring of Cancer Incidence in Japan (MCIJ) project. Jpn J Clin Oncol 45(9):884\u2013891","journal-title":"Jpn J Clin Oncol"},{"issue":"6","key":"1526_CR4","doi-asserted-by":"publisher","first-page":"1063","DOI":"10.1007\/s00280-017-3417-3","volume":"80","author":"N Matsubara","year":"2017","unstructured":"Matsubara N, Mukai H, Hosono A et al (2017) Phase 1 study of darolutamide (ODM-201): a new-generation androgen receptor antagonist, in Japanese patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol 80(6):1063\u20131072","journal-title":"Cancer Chemother Pharmacol"},{"key":"1526_CR5","doi-asserted-by":"publisher","first-page":"2141","DOI":"10.2147\/OTT.S147168","volume":"11","author":"JT Chong","year":"2018","unstructured":"Chong JT, Oh WK, Liaw BC (2018) Profile of apalutamide in the treatment of metastatic castration-resistant prostate cancer: evidence to date. OncoTargets Ther 11:2141\u20132147","journal-title":"OncoTargets Ther"},{"issue":"6","key":"1526_CR6","doi-asserted-by":"publisher","first-page":"1494","DOI":"10.1158\/0008-5472.CAN-11-3948","volume":"72","author":"NJ Clegg","year":"2012","unstructured":"Clegg NJ, Wongvipat J, Joseph JD et al (2012) ARN-509: a novel anti-androgen for prostate cancer treatment. Cancer Res 72(6):1494\u20131503","journal-title":"Cancer Res"},{"issue":"6","key":"1526_CR7","doi-asserted-by":"publisher","first-page":"963","DOI":"10.1016\/j.eururo.2016.04.023","volume":"70","author":"MR Smith","year":"2016","unstructured":"Smith MR, Antonarakis ES, Ryan CJ et al (2016) Phase 2 study of the safety and antitumor activity of apalutamide (ARN-509), a potent androgen receptor antagonist, in the digh-risk nonmetastatic castration-resistant prostate cancer cohort. Eur Urol 70(6):963\u2013970","journal-title":"Eur Urol"},{"issue":"7","key":"1526_CR8","doi-asserted-by":"publisher","first-page":"1148","DOI":"10.1200\/JCO.2007.12.4487","volume":"26","author":"HI Scher","year":"2008","unstructured":"Scher HI, Halabi S, Tannock I et al (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the prostate cancer clinical trials working group. J Clin Oncol 26(7):1148\u20131159","journal-title":"J Clin Oncol"},{"issue":"28","key":"1526_CR9","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1200\/JCO.2013.50.1684","volume":"31","author":"DE Rathkopf","year":"2013","unstructured":"Rathkopf DE, Morris MJ, Fox JJ et al (2013) Phase I study of ARN-509, a novel antiandrogen, in the treatment of castration-resistant prostate cancer. J Clin Oncol 31(28):3525\u20133530","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"1526_CR10","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1200\/JCO.2017.35.6_suppl.204","volume":"35","author":"DE Rathkopf","year":"2017","unstructured":"Rathkopf DE, Slovin SF, Morris MJ et al (2017) Targeting reciprocal feedback inhibition: Apalutamide and everolimus in patients with metastatic castration-resistant prostate cancer (mCRPC). J Clin Oncol 35(6_suppl):204","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"1526_CR11","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1200\/JCO.2017.35.6_suppl.173","volume":"35","author":"EM Posadas","year":"2017","unstructured":"Posadas EM, Chi KN, Wit RD et al (2017) Phase Ib study of apalutamide (APA) with abiraterone acetate (AA) and prednisone (P) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): update on safety and efficacy. J Clin Oncol 35(6_suppl):173","journal-title":"J Clin Oncol"},{"issue":"9","key":"1526_CR12","doi-asserted-by":"publisher","first-page":"2264","DOI":"10.1093\/annonc\/mdx283","volume":"28","author":"DE Rathkopf","year":"2017","unstructured":"Rathkopf DE, Smith MR, Ryan CJ et al (2017) Androgen receptor mutations in patients with castration-resistant prostate cancer treated with apalutamide. Ann Oncol 28(9):2264\u20132271","journal-title":"Ann Oncol"},{"key":"1526_CR13","unstructured":"FDA approves apalutamide for non-metastatic castration-resistant prostate cancer. Available via DIALOG. \nhttps:\/\/www.fda.gov\/Drugs\/InformationOnDrugs\/ApprovedDrugs\/ucm596796.htm\n\n. Accessed Oct 2018"},{"key":"1526_CR14","unstructured":"List of approved products in Pharmaceuticals and Medical Devices Agency (PMDA). \nhttps:\/\/www.pmda.go.jp\/files\/000229856.pdf#page=8\n\n. Accessed June 2019"},{"issue":"15","key":"1526_CR15","doi-asserted-by":"publisher","first-page":"1408","DOI":"10.1056\/NEJMoa1715546","volume":"378","author":"MR Smith","year":"2018","unstructured":"Smith MR, Saad F, Chowdhury S et al (2018) Apalutamide treatment and metastasis-free survival in prostate cancer. N Engl J Med 378(15):1408\u20131418","journal-title":"N Engl J Med"},{"key":"1526_CR16","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1903307","author":"KN Chi","year":"2019","unstructured":"Chi KN, Agarwal N, Bjartell A et al (2019) Apalutamide for metastatic, castration-sensitive prostate cancer. N Engl J Med. \nhttps:\/\/doi.org\/10.1056\/NEJMoa1903307","journal-title":"N Engl J Med"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10147-019-01526-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-019-01526-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,8,22]],"date-time":"2020-08-22T23:28:34Z","timestamp":1598138914000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10147-019-01526-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8,24]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2019,12]]}},"alternative-id":["1526"],"URL":"https:\/\/doi.org\/10.1007\/s10147-019-01526-7","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8,24]]},"assertion":[{"value":"26 March 2019","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 July 2019","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2019","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Dr. Hiroji Uemura received grants from Janssen Pharmaceutical K.K.(during the conduct of the study) and from Bayer Yakuhin, Limited, Takeda Pharmaceutical Company Limited, AstraZeneca K.K., TAIHO Pharmaceutical Company Limited, Astellas Pharma Inc. and Pfizer Inc (outside the research work, lecture, or subsidies). Dr. Katsuyoshi Hashine received grants from Janssen Pharmaceutical (during the conduct of the study) and from Takeda Pharmaceutical (subsidies). Dr. Tomohiro Tsuchiya and Dr. Akito Yamaguchi received grants from Janssen Pharmaceutical K.K. during the conduct of the study. Dr. Keiichiro Imanaka, Ms. Yuki Iwaki, and Mr. Ryo Oyama are employees of Janssen Pharmaceutical K.K.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}